Global Anticoagulant Registry in the Field
| Status: | Recruiting |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | December 2009 |
| End Date: | July 2018 |
| Contact: | Gloria Kayani |
| Email: | gkayani@tri-london.ac.uk |
| Phone: | 00442073518390 |
Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.
The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is
a pioneering real-world prospective registry - one of the largest in the field of
non-valvular atrial fibrillation (AF). With an eventual enrolment target of 55,000 patients,
GARFIELD-AF aims to enhance understanding of stroke prevention in patients with non-valvular
AF worldwide and help in defining future treatment strategies that may eventually influence
patient outcomes.
a pioneering real-world prospective registry - one of the largest in the field of
non-valvular atrial fibrillation (AF). With an eventual enrolment target of 55,000 patients,
GARFIELD-AF aims to enhance understanding of stroke prevention in patients with non-valvular
AF worldwide and help in defining future treatment strategies that may eventually influence
patient outcomes.
Using data from more than 1000 randomly selected centres across 35 countries, representing
all possible care settings, the registry will help to characterize real-life anticoagulant
treatment patterns and outcomes, including rates of stroke and bleeding complications, as
well as provide data on other important issues, such as physicians' compliance with
guidelines and patients' adherence to therapy. This is particularly timely as standard
practice moves away from vitamin K antagonist (VKA)-dominated therapy and towards a new era
of novel oral anticoagulants (OACs), i.e. direct Factor Xa inhibitors and direct thrombin
inhibitors.
To ensure a dataset that truly reflects current practice, the investigators are requested to
prospectively enrol all newly diagnosed patients with non-valvular AF who have at least one
additional investigator-determined risk factor for stroke. Patients are consecutively
recruited into one of five cohorts and followed up for at least 2 years.
With 3 cohorts complete and 36,000 enrolled GARFIELD-AF continues to recruit patients and,
in conjunction with other registries and non-interventional studies, will be the source of
further informative and useful data in the coming years. The findings will serve to increase
our understanding of the management of patients with AF and improve our practice for their
benefit.
all possible care settings, the registry will help to characterize real-life anticoagulant
treatment patterns and outcomes, including rates of stroke and bleeding complications, as
well as provide data on other important issues, such as physicians' compliance with
guidelines and patients' adherence to therapy. This is particularly timely as standard
practice moves away from vitamin K antagonist (VKA)-dominated therapy and towards a new era
of novel oral anticoagulants (OACs), i.e. direct Factor Xa inhibitors and direct thrombin
inhibitors.
To ensure a dataset that truly reflects current practice, the investigators are requested to
prospectively enrol all newly diagnosed patients with non-valvular AF who have at least one
additional investigator-determined risk factor for stroke. Patients are consecutively
recruited into one of five cohorts and followed up for at least 2 years.
With 3 cohorts complete and 36,000 enrolled GARFIELD-AF continues to recruit patients and,
in conjunction with other registries and non-interventional studies, will be the source of
further informative and useful data in the coming years. The findings will serve to increase
our understanding of the management of patients with AF and improve our practice for their
benefit.
Inclusion Criteria:
Prospective Cohort
- Written informed consent
- Age 18 years and older
- New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks)
with at least one additional risk factor for stroke and regardless of therapy.
Retrospective validation cohort
- Written informed consent
- Age 18 years and older
- Diagnosis of non-valvular AF (diagnosed 6-24 months prior to enrolment) with at least
one additional risk factor for stroke and regardless of therapy.
Exclusion criteria:
- No further follow-up envisaged or possible within enrolling hospital or with
associated family practitioner.
- Patients with transient AF secondary to a reversible cause.
- Patients recruited in controlled clinical trials.
We found this trial at
1
site
Click here to add this to my saved trials
